Brello Weight Loss Program: Model, Eligibility, and Costs

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This page belongs to the PlexusDx Education Hub, where we unpack GLP-1 therapy, weight management protocols, and the genetic factors sitting underneath every metabolic decision. Browse all Peptides & GLP-1 education

What follows is an independent editorial review. PlexusDx holds no commercial relationship with Brello or its parent company, and nothing here involves affiliate links or paid placement.

Brello is one of many telehealth brands competing in the GLP-1 weight-management category. Below we walk through who the program is aimed at, how a Brello weight-loss consultation actually unfolds, the medication menu, and the one variable the intake form never captures. This is fair-balance context, not a purchase recommendation, current as of April 2026.

Who Brello is built for

Brello (Brello Health) runs on a telehealth-plus-compounded-pharmacy model. In practice that means a virtual evaluation by a licensed provider, a prescription routed either to a retail pharmacy for an FDA-approved brand product or to a 503A compounding pharmacy for compounded semaglutide or tirzepatide, and continued follow-up afterward. The typical candidate is an adult seeking clinician-supervised GLP-1 support without an in-person clinic visit. For current program structure and pricing, consult Brello's official website (search for its current URL at the time you read this).

Inside a Brello weight-loss consultation

The workflow mirrors most telehealth GLP-1 programs. First, you complete an intake covering weight, medical history, and current medications. Second, a licensed clinician reviews that intake and, if you meet eligibility, writes a prescription. Third, the prescription is sent to either a retail pharmacy or a licensed compounding pharmacy for fulfillment. Fourth, ongoing telehealth check-ins support dose titration and side-effect management. Where programs diverge is in provider type (physician versus NP or PA), pharmacy partner (retail versus compounded), and how the subscription is packaged.

What eligibility and cost look like

Brello publishes its own pricing, and what you ultimately spend depends on the product chosen (semaglutide versus tirzepatide versus another option), the subscription tier, and whether the brand dispenses an FDA-approved brand product or a compounded alternative. Across the telehealth GLP-1 market, monthly totals as of April 2026 span roughly $200 to $700 or more, with wide variance. Because these numbers move frequently, confirm current figures on Brello's official website before committing to anything.

The evidence behind GLP-1 weight management

Any legitimate program's pharmacology traces back to the underlying compound class: GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and GIP/GLP-1 dual agonists (tirzepatide). The pivotal trial programs are STEP (semaglutide for weight management, The New England Journal of Medicine, 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Trial populations and endpoints differ, and individual outcomes vary.

The upstream variable Brello's intake can't see

No telehealth intake like Brello's maps the genetic architecture that shapes how a body responds to any GLP-1 compound. Variants in FTO (the fat-mass and obesity-associated gene), GLP1R (the GLP-1 receptor gene, the direct target of every GLP-1 compound), MC4R (a melanocortin receptor central to satiety and energy balance), and TCF7L2 (a transcription factor tied to glucose homeostasis and GLP-1 secretion) describe the baseline metabolic terrain a compound acts on. These are pathway-level markers. They do not predict response to any specific drug, but they do describe the biology a clinician is prescribing into, context a prescription alone never records.

PlexusDx offers semaglutide and tirzepatide inside its Weight Management Protocols, available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. The distinguishing piece is what comes first. Before any GLP-1 pathway protocol, the Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, including the FTO, MC4R, and TCF7L2 variants that shape baseline GLP-1, appetite-regulation, and energy-balance biology. Pairing that profile with the protocol is the test before you invest approach, replacing guesswork with an informed conversation alongside your provider.

Not affiliated: PlexusDx is not affiliated with Brello and holds no commercial relationship with any company named in this review.

Related reading on PlexusDx: Semaglutide Tablets For Weight Loss, Tirzepatide vs Semaglutide For Weight Loss, Ozempic And Weight Loss, Diabetes Weight Loss Drug.

Disclaimer: This article is educational. PlexusDx is not affiliated with Brello and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols, and this review compares approaches within the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach: see the Weight Management Protocols, semaglutide and tirzepatide with the genetic context most telehealth programs skip. Or begin upstream and take the Precision Peptide Genetic Test to understand your GLP-1 pathway first.

Frequently Asked Questions

Who qualifies for a Brello weight-loss program?

Eligibility is determined by a licensed clinician after reviewing your intake, which covers weight, medical history, and current medications. Programs in this model generally screen for contraindications before prescribing. Brello publishes its own criteria, so confirm the current requirements and provider credentials on the brand's own website before paying.

Does Brello prescribe brand-name or compounded medication?

Telehealth programs in this category dispense either FDA-approved brand products through a retail pharmacy or compounded semaglutide or tirzepatide through a 503A compounding pharmacy. Which one applies depends on the plan you select and clinical judgment. Verify the dispensing pathway directly with Brello, since compounded and brand products are legally distinct.

How does the Precision Peptide Genetic Test fit alongside a program like Brello?

It does not predict how you will respond to Brello or any specific compound. It analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology, upstream context that stays relevant no matter which telehealth service writes the prescription.

How is PlexusDx different from Brello?

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols and pairs them with the Precision Peptide Genetic Test for upstream context. The difference is pathway-level genetic insight delivered alongside the medication itself, something telehealth-only programs like Brello generally do not provide.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.